GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bone Biologics Corp (NAS:BBLG) » Definitions » Cash per Share

BBLG (Bone Biologics) Cash per Share : $1.13 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Bone Biologics Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Bone Biologics's Cash per Share for the quarter that ended in Dec. 2024 was $1.13.

Bone Biologics Cash per Share Historical Data

The historical data trend for Bone Biologics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bone Biologics Cash per Share Chart

Bone Biologics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 155.23 117.78 5.67 1.13

Bone Biologics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.67 3.18 1.77 1.70 1.13

Bone Biologics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Bone Biologics's Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=3.325/2.95
=1.13

Bone Biologics's Cash per Share for the quarter that ended in Dec. 2024 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=3.325/2.95
=1.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bone Biologics  (NAS:BBLG) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Bone Biologics Cash per Share Related Terms

Thank you for viewing the detailed overview of Bone Biologics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Bone Biologics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bone Biologics Corp (NAS:BBLG) » Definitions » Cash per Share
Comparable Companies
USAQ VTAK HSDT NAOV TLIS ALRTF HSCS VYCO BJDX VERO ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
N/A
Address
2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803
Website
https://www.bonebiologics.com
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Executives
Deina H Walsh officer: Chief Financial Officer 175, MAY STREET, EDISON NJ 08837
Jeff Frelick officer: Chief Operating Officer 1 FOX RUN LANE,, LEXINGTON MA 02420
Knight Insurance Company, Ltd 10 percent owner 4751 WILSHIRE BLVD.,, SUITE 111, LOS ANGELES CA 90010
Siddhesh Rajendra Angle director 481 MONMOUTH ST, UNIT G,, JERSEY CITY NJ 07302
Erick Lucera director 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Don Hankey director, 10 percent owner, officer: Chairman of the Board 4751 WILSHIRE BLVD., SUITE 110, LOS ANGELES CA 90010
Bret Hankey director 4751 WILSHIRE BLVD. #110, LOS ANGELES CA 90010
Hankey Capital, Llc 10 percent owner 4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Don Hankey Trust 10 percent owner 4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Amir F Heshmatpour 10 percent owner 269 S. BEVERLY DRIVE, STE #1600, BEVERLY HILLS CA 90212
Musculoskeletal Transplant Foundation, Inc. director 175 MAY STREET, SUITE 300, EDISON NJ 08837
Benjamin Wu director 2740 LORAIN ROAD, SAN MARINO CA 91108
La Neve Stephen R. director, officer: CEO and President 106 MCCOOL BLVD, WEST CHESTER PA 19380
George A Oram director 12 EDGEMONT LANE, BEDMINSTER NJ 07921
Jim Delshad director 132 S. MAPLE DR., BEVERLY HILLS CA 90212